Related Experiment Video
Updated: Mar 28, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Long-term medication persistence in stroke patients treated with intravenous thrombolysis
Maja Stefanovic Budimkic1, Tatjana Pekmezovic2, Ljiljana Beslac-Bumbasirevic3
1Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
Insights
Stroke survivors receiving intravenous thrombolysis (IVT) showed better long-term medication persistence for secondary prevention. Higher medication adherence was linked to better functional outcomes post-stroke.
Area of Science:
- Neurology
- Pharmacology
- Public Health
Background:
- Long-term medication persistence is crucial for secondary stroke prevention.
- Data on medication persistence in stroke survivors treated with intravenous thrombolysis (IVT) is limited.
- Understanding medication adherence post-IVT is vital for optimizing patient outcomes.
Purpose of the Study:
- To evaluate long-term medication persistence in stroke patients treated with IVT.
- To compare medication persistence between IVT-treated and non-IVT-treated stroke patients.
- To identify factors associated with medication persistence after acute ischemic stroke.
Main Methods:
- Retrospective observational study of 203 IVT-treated and 197 non-IVT-treated acute ischemic stroke patients.
- Median follow-up period of 3 years (range 1-7 years).
- Analysis of secondary stroke prevention medications including anti-thrombotics, anti-hypertensives, statins, and hypoglycemics.
Main Results:
- IVT-treated patients demonstrated significantly higher medication persistence (88.7%) compared to non-IVT-treated patients (69.0%).
- IVT was an independent predictor of medication persistence (OR=2.93, 95% CI=1.48-5.81).
- Higher medication persistence correlated with favorable long-term functional outcomes in both IVT and non-IVT groups.
Conclusions:
- Stroke patients treated with IVT exhibit superior long-term medication persistence.
- Lower medication persistence is associated with greater post-stroke disability.
- Improving medication adherence in stroke survivors, particularly those with disabilities, is essential for secondary prevention.
Objective:
There are no data regarding long-term medication persistence in stroke survivors treated with intravenous thrombolysis (IVT), which is one of the most important determinants of treatment success. Our objective was to determine long-term medication persistence in stroke patients treated with IVT.
Methods:
This retrospective observational study included 203 IVT-treated and 197 non-IVT treated patients with acute ischemic strokes (IS) admitted to the Stroke Unit between January 2007 and January 2013.
Results:
During a median follow-up period of 3 years (range 1-7 years), 56 (21.6%) patients in the IVT-group and 62 (23.9%) patients in the non-IVT-group died. There was a higher medication persistence for all secondary stroke prevention medications (anti-thrombotic agents, anti-hypertensive drugs, statins and hypoglycemic drugs) in the IVT-group compared to the non-IVT group (88.7% vs. 69.0%; OR=3.68, 95% CI=2.17-6.23). After adjusting for baseline characteristics and possible confounders IVT was the independent predictor of medication persistence (OR=2.93, 95% CI=1.48-5.81, p=0.002). Higher medication persistence was observed in patients with favorable long-term functional outcome, both in the IVT-group (OR=4.37, 95% CI=1.83-10.40, p<0.001) and the non-IVT-group (OR=3.46, 95% CI=1.84-6.52, p<0.001).
Conclusion:
Medication persistence was higher among IVT-treated patients compared to non-IVT-treated patients. The higher rate of non- medication persistence was recorded among patients with more pronounced disabilities after stroke.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism III: Nursing Management
Venous Thrombosis IV: Nursing Management

